Mount Sinai Neurosurgery

Had a fantastic evening at Theodore's Books with the Mount Sinai Health System Department of Neurosurgery and our amazing patient, Long Island triathlete and businesswoman Hilary Topper! Hilary read chapters from her inspiring book, "From Couch Potato to Endurance Athlete," while Mount Sinai Physician Assistant Emily Nitzberg, MS, PA-C , spoke about #brainaneurysms, early detection, and key signs to look for. Hilary shared a touching chapter about her sister Lori, who sadly passed away from an undetected aneurysm, and how she feels Lori saved her life by inspiring her to get checked. IF YOU HAVE A DIRECT FAMILY MEMBER WHO DIED FROM A BRAIN ANEURYSM, DON'T WAIT!  Thanks to the support of THE BEE FOUNDATION who helped connect Hilary to her cerebrovascular neurosurgeon, Christopher Kellner, MD , and Emily Nitzberg who helped cure her!

Congratulations to Neha Dangayach , MD, MSCR, on being honored as a Fellow of the American Neurological Association (FANA)! 🎉 🥳 ✨

TODAY at #SNIS2024: Christopher Kellner, MD will be presenting on the Nautilus Endovascular Device! See you there!✨

TODAY at #SNIS2024: Shahram Majidi, MD will be presenting on Endovascular Motor Neuroprosthesis! Excited to learn! 🤓✨

Today on July 22nd, the Mount Sinai Health System Department of Neurosurgery honors #WorldBrainDay! Let's celebrate the incredible power of the brain and the advancements in neurosurgery that protect and enhance brain health. 🧠✨

Florian, an active rock climber and runner, collapsed in #NYC, he was rushed to Mount Sinai Health System with a #brainhemorrhage. Tomoyoshi Shigematsu, MD, PhD performed life-saving surgery. Now, Florian is running again and regaining his strength. Read More: https://bit.ly/3Sjh3Oz

🔬🧬Hope for Glioblastoma: Better Access and Genetic Profiling for Equitable Treatments🔬🧬 Glioblastoma (GB) is a deadly and complex brain malignancy, with over 14,490 new cases and 10,000 deaths in the US in 2023. Recent studies show disparities in GB diagnosis and outcomes among different racial groups, likely influenced by socioeconomic status and barriers to health care access. For instance, in Alabama, African Americans with GB had worse survival rates compared to non-Hispanic Whites. The study, "Patients with Glioblastoma: A Tale of Health Care Access and Genetic Ancestry," published in Cancer by the American Cancer Society, was conducted by Mount Sinai Neurosurgery's Dr. Isabelle Germano, and neurosurgery medical students Zerubabbel Asfaw and Gianina Hernandez-Marquez. Their research revealed that 45% of GB patients were non-White, indicating that better healthcare access could lead to more representation. The study highlighted the need for a two-pronged approach: addressing social determinants of health to improve access and using genetic profiling to refine treatment strategies. This research brings hope that improving healthcare access and utilizing genetic profiling can lead to better, more equitable glioblastoma treatments. Read more: https://lnkd.in/e34JxyN9

Today, on July 17th, we honor Glioblastoma Awareness Day. Glioblastoma is the most aggressive form of brain cancer, with a survival rate of only 6.9%. It accounts for approximately 48% of all primary malignant brain tumors. Mount Sinai Health System’s Department of Neurosurgery is dedicated to raising awareness, supporting research, and standing with those affected by and fighting against glioblastoma.

Published in Neurosurgery, the Mount Sinai Cerebrovascular Center studied anesthesia modalities used for endovascular thrombectomy (EVT) in distal and medium vessel occlusions, comparing conscious sedation (CS) with general anesthesia (GA) for distal vessel thrombectomy. The research aimed to uncover which method provides better outcomes for patients suffering from acute ischemic stroke.  Led by Drs. Christopher Kellner, Reade DeLeacy, Johanna Fifi, J Mocco, and Shahram Majidi, Amol Mehta, and Daryl Goldman, and researcher Preethi Reddi, key findings include:     •    CS was associated with higher odds of early neurological improvement.     •    CS led to higher rates of successful reperfusion complared to GA     •    CS showed a trend toward lower mortality rates (although not statistically significant)     •    Both CS and GA were found to be safe and feasible with no significant differences in 90-day outcomes, intracerebral or subarachnoid hemorrhages, and first-pass effect Conclusion: CS during EVT for distal and medium vessel occlusions is safe and may lead to better immediate outcomes, offering potential benefits for early neurological outcomes and successful recanalization. 🧠✨ Check out the full study in Neurosurgery: https://bit.ly/4bujxAl

🏃♂️🏃♀️ Join the Mount Sinai Health System's Department of Neurosurgery for the 11th Annual TeamCindy 5K Run for Research on Saturday, September 14, 2024, at 7:00 AM at Hudson River Park, NYC – Pier 62! 🧠 In honor of Cindy Sherwin, a young woman who passed away from an unexpected brain aneurysm, this event supports the Brain Aneurysm Foundation, raising awareness and funds to prevent brain aneurysms. Enjoy a family-friendly atmosphere with prizes, a dance party, and music by DJ Bastic. Together, we can make a difference! For more info and to register or donate, visit https://lnkd.in/dRHnzTFU